Trademark: 97249797
Word
DTX PHARMA
Status Date
Thursday, July 11, 2024
Filing Date
Wednesday, February 2, 2022
Published for Opposition
Tuesday, May 23, 2023
5 Pharmaceutical preparations, namely, oligonucleotide compounds; oligonucleotide compounds for the treatment of genetic diseases; oligonucleotide delivery agents in the form of intravenous infusion or injection, suspension or sterile powder for the treatment of genetic diseases; pharmaceutical preparations for the treatment of genetic diseases; therapeutic preparations using RNA to treat ocular, neuromuscular and central nervous system (CNS) diseases; fatty acid-based oligonucleotide delivery agents in the form of intravenous infusion or injection, suspension or sterile powder for the treatment of genetic diseases
42 Pharmaceutical research and development of oligonucleotide compounds; scientific research and product development in the field of oligonucleotide compounds and drug discovery; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in therapeutic discovery and development; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in the treatment of genetic diseases; Pharmaceutical research and development of therapeutic preparations using RNA to treat ocular, neuromuscular and central nervous system (CNS) diseases
Feb 5, 2022
New Application Entered
Feb 8, 2022
New Application Office Supplied Data Entered
Oct 11, 2022
Assigned To Examiner
Oct 24, 2022
Non-Final Action Written
Oct 24, 2022
Non-Final Action E-Mailed
Oct 24, 2022
Notification Of Non-Final Action E-Mailed
Apr 19, 2023
Examiners Amendment -Written
Apr 19, 2023
Examiners Amendment E-Mailed
Apr 19, 2023
Notification Of Examiners Amendment E-Mailed
Apr 19, 2023
Examiner's Amendment Entered
Apr 19, 2023
Approved For Pub - Principal Register
May 3, 2023
Notification Of Notice Of Publication E-Mailed
Jul 18, 2023
Noa E-Mailed - Sou Required From Applicant
May 23, 2023
Published For Opposition
May 23, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 12, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Dec 12, 2023
Teas Change Of Correspondence Received
Dec 12, 2023
Teas Withdrawal Of Attorney Received-Firm Retains
Dec 12, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 8, 2024
Sou Teas Extension Received
Jan 8, 2024
Sou Extension 1 Filed
Jan 8, 2024
Sou Extension 1 Granted
Jan 10, 2024
Notice Of Approval Of Extension Request E-Mailed
Jul 11, 2024
Sou Teas Extension Received
Jul 11, 2024
Notice Of Approval Of Extension Request E-Mailed
Jul 11, 2024
Sou Extension 2 Granted
Jul 11, 2024
Sou Extension 2 Filed
Trademark Alertz updated from USPTO on 2030-01-24
